STENTYS Enrolls First Patient in Left Main Clinical Trial

STENTYS Enrolls First Patient in Left Main Clinical Trial The TRUNC study is designed to evaluate Xposition S efficacy in 200 patients suffering from Left Main disease 

PRINCETON, N.J. and PARIS., STENTYS, a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has commenced enrolling patients in the TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease. 

The first implantation was performed at Treant hospital in Emmen, the Netherlands. Dr Rutger Anthonio and Dr Gillian Jessurun commented: "The procedure went very smoothly. The Xposition S stent is perfectly suited for the treatment of left main lesions, because it guarantees excellent apposition in a vessel segment with substantial diameter variation. In addition, the stent allows easy access to any anatomical side branch without the need to perform kissing balloon inflation, which minimizes overall manipulation." 

Christophe Lottin, Chief Executive Officer of STENTYS, adds: "We are delighted by the start of this study, as left main interventions account for nearly 10% of PCI. We are aiming to demonstrate that the unique properties of our Self-Apposing technology make it the most optimal treatment for this complex indication."

Source: STENTYS